Regular PaperImpact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients
References (14)
- et al.
Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications
J Hepatol
(1992) - et al.
Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients
Lancet
(1991) - et al.
Quantification of hepatitis B virus DNA (HBV DNA) in serum using the spot hybridisation technique and scintillation counting
J Virol Meth
(1985) - et al.
Follow-up of recurrent hepatitis B and delta infection in liver allograft recipients after treatment with recombinant interferon-α
J Hepatol
(1991) - et al.
Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization
J Hepatol
(1991) - et al.
Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
Hepatology
(1991) - et al.
Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model
Transplantation
(1990)
Cited by (51)
Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B
2021, Revista de Gastroenterologia de MexicoImmunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection
2017, Transplantation ReviewsCitation Excerpt :In the beginning of the 1990’s two seminal studies by Samuel et al. demonstrated that the recurrence of HBV after LTx could be significantly reduced by high dose HBIg therapy [74,75]. Administration of 10,000 international units (IU) HBIg intra-operatively during the anhepatic phase, daily infusions of 10,000 IU HBIg during the first post-transplant week, followed by 10,000 IU per month thereafter, decreased recurrence rates to 20%–40%, resulting in improved survival rates, comparable with those of non-HBV LTx recipients [74–77]. However, HBIg monotherapy could not prevent HBV-recurrence in most patients with high viral load at the time of LTx.
Strategies for avoiding hepatitis B infection recurrence following liver transplantation
2014, Gastroenterologia y HepatologiaPrevention of recurrent hepatitis B infection after liver transplantation
2013, Hepatobiliary and Pancreatic Diseases InternationalDoes pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIG and Nucleoside Analogues?
2011, Annals of HepatologyCitation Excerpt :The only patient in our cohort with an HBV-DNA level ≥ 105 IU/mL who received HBIg and LAM did not experience HBV recurrence. This contrasts with results from earlier reports1,34,35 but is similar those described in recent studies.24,28,29,36 Hence, the presence of viral replication should not be considered an absolute contraindication for liver transplantation if an adequate postoperative prophylaxis is used.28,29
HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration
2007, Journal of HepatologyCitation Excerpt :Hepatitis B recurrence was frequent in absence of hepatitis B reinfection prophylaxis after liver transplantation (OLT), resulting in considerably reduced graft and patient survival [1,2]. Reinfection rates dropped and survival improved significantly with the use of hepatitis B immunoglobulin (HBIG) prophylaxis [3–19]. High viral replication at time of transplantation was shown to be the key risk factor for reinfections in patients receiving HBIG mono-prophylaxis [7,12,20,21].